Fifth Third Bancorp Purchases 1,521 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Fifth Third Bancorp boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 13.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,179 shares of the medical research company's stock after purchasing an additional 1,521 shares during the period. Fifth Third Bancorp's holdings in IQVIA were worth $2,590,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the third quarter worth about $27,000. Park Place Capital Corp bought a new position in IQVIA in the 3rd quarter worth approximately $28,000. Avior Wealth Management LLC lifted its holdings in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after buying an additional 87 shares in the last quarter. Assetmark Inc. boosted its position in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after buying an additional 196 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in shares of IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company's stock valued at $55,000 after buying an additional 99 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently commented on IQV. BTIG Research lowered their price objective on IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Morgan Stanley dropped their price target on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Stephens initiated coverage on shares of IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Robert W. Baird cut their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus target price of $255.71.

IQVIA Stock Performance

IQVIA stock traded down $3.41 during midday trading on Tuesday, hitting $203.59. The company's stock had a trading volume of 1,258,391 shares, compared to its average volume of 1,329,646. The company has a 50-day moving average price of $200.02 and a two-hundred day moving average price of $221.09. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a market cap of $36.95 billion, a price-to-earnings ratio of 26.72, a PEG ratio of 2.14 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.